Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Fig. 2

Change from baseline to week 52 in PtGA VAS and FACIT-Fatigue scores. Improvement is indicated by a negative change in PtGA and a positive change in FACIT-Fatigue score. *p < 0.001 vs TCZ-QW + Pred-26, upper dashed line = FACIT-Fatigue MCID, lower dashed line = PtGA MCID. FACIT Functional Assessment of Chronic Illness Therapy, MCID minimum clinically important difference, PBO placebo, Pred-26 26-week prednisone taper, Pred-52 52-week prednisone taper, PtGA Patient Global Assessment of Disease Activity, QW every week, TCZ tocilizumab

Back to article page